Recipharm Inks Vaccine Manufacturing Deal with Top 10 Big Pharma Company


CDMO will use its BFS knowledge to support production out of its Kaysersberg, France plant

Recipharm, contract development and manufacturing organization (CDMO), has secured a contract with a top 10 big pharma company to support vaccine manufacturing from its facility in Kaysersberg, France.

Although the pharma powerhouse with whom the deal was signed went unnamed, the agreement was announced after a successful quality audit, and will see the CDMO aseptically pack single-use vaccines that are used to treat a severe infectious disease that affects both young children and infants. The containers are to be filled using Recipharm’s specialist blow-fill-seal (BFS) capabilities.

In order to help meet this capacity, Recipharm plans to hire over 30 employees between 2022 and 2026, as the product scales towards commercial production. The company is investing close to $16 million towards its vaccine manufacturing efforts.

“We are very proud to be supporting a big pharma partner in the delivery of a vital vaccine to the market,” comments Yves Buelens, general manager at Recipharm’s facility in Kaysersberg. “This deal is indicative of Recipharm’s successful and ongoing product portfolio diversification. We’ve invested heavily into new capabilities that have built on our BFS expertise, and as a result, strengthened our biotech offering. We are now in a position to welcome new biopharma projects to the Kaysersberg site.”

Related Videos
© 2024 MJH Life Sciences

All rights reserved.